Rongta Tech (09881) will be suspended from trading starting from April 1st, awaiting the publication of the full-year performance for 2025.
Rongda Technology (09881) announced that according to Rule 13.49 of the Listing Rules, the company is required to publish its annual performance announcement within three months after the end of the financial year, i.e. by March 31, 2026. The Board of Directors hereby notifies the company's shareholders and potential investors that due to additional time needed by the company's auditors to complete necessary audit work, the publication of the annual performance announcement will be delayed. The Board of Directors anticipates that the annual performance announcement will be published within April 2026. The company will issue a separate announcement at the appropriate time, informing shareholders and potential investors of details of the outstanding audit work, the expected timeline for completion of the audit work, and the exact publication date of the annual performance.
RONGTA TECH (09881) announced that, in accordance with Rule 13.49 of the Listing Rules, the company is required to publish its annual results announcement within three months after the end of the fiscal year (i.e. on or before March 31, 2026). The Board of Directors hereby notifies the company's shareholders and potential investors that, due to the need for additional time for the company's auditors to complete the necessary audit work, the annual results announcement will be delayed. The Board anticipates that the annual results announcement will be published within April 2026. The company will issue a separate announcement at the appropriate time, informing shareholders and potential investors about details of the ongoing audit work, expected time schedule for completion of audit work, and the exact publication date of the annual results.
Trading of the company's H shares on the Stock Exchange will be suspended from 9:00 am on April 1, 2026, pending the publication of the annual results announcement.
Related Articles
HK Stock Market Move | INSILICO (03696) rose more than 10% in early trading, the company reached a $2.75 billion cooperation agreement with Lilly, the CEO stated their willingness to maintain independence.
SUNHO BIO-B(02898) will be suspended from trading starting April 1st, pending the publication of its full-year performance for 2025.
HK Stock Market Move | Pharmaron Beijing (03759) rose by over 7%. The overall performance of the company is accelerating positively, with the amount of new signed orders last year increasing by over 14%.
HK Stock Market Move | INSILICO (03696) rose more than 10% in early trading, the company reached a $2.75 billion cooperation agreement with Lilly, the CEO stated their willingness to maintain independence.
SUNHO BIO-B(02898) will be suspended from trading starting April 1st, pending the publication of its full-year performance for 2025.
HK Stock Market Move | Pharmaron Beijing (03759) rose by over 7%. The overall performance of the company is accelerating positively, with the amount of new signed orders last year increasing by over 14%.
